All Stories

  1. Comparison of rivaroxaban and low molecular weight heparin in the treatment of cancer-associated venous thromboembolism: a Swedish national population-based register study
  2. Lessons learned from a multi‐data source research collaboration: The mirabegron post‐authorization safety study program
  3. Consistency between the National Patient Register and the Swedish Cancer Register
  4. Characteristics and hormonal contraception use patterns of levonorgestrel 13.5 mg intrauterine device users in Sweden 2014–2016
  5. Estrogen-modulating treatment among mid-life women and COVID-19 morbidity and mortality: a multiregister nationwide matched cohort study in Sweden
  6. A global systematic overview of socioeconomic factors associated with antidiabetic medication adherence in individuals with type 2 diabetes
  7. The association between exposure to clozapine, olanzapine, and quetiapine and the outcomes perimyocarditis and heart failure: A population-based cohort study
  8. COVID-19 and comedications in atrial fibrillation—a case–control study in Stockholm
  9. Bleeding events among patients concomitantly treated with direct oral anticoagulants and macrolide or fluoroquinolone antibiotics
  10. 1591P Swedish national population-based study of direct oral anticoagulants and low molecular weight heparin treatment for thromboembolism in cancer patients: The OSCAR SWE study
  11. Covid-19 and comedications in atrial fibrillation – a case-control study in Stockholm
  12. Rationale and performances of a data-driven method for computing the duration of pharmacological prescriptions using secondary data sources
  13. Method of Hormonal Contraception and Protective Effects Against Ectopic Pregnancy
  14. Patient characteristics and safety outcomes in new users of ticagrelor and clopidogrel—An observational cohort study in Sweden
  15. The use of uncertain exposure—A method to define switching and add‐on in pharmacoepidemiology
  16. Lessons Learned Using Real‐World Data to Emulate Randomized Trials: A Case Study of Treatment Effectiveness for Newly Diagnosed Immune Thrombocytopenia
  17. Risk factors of hospitalisation for thrombosis in adults with primary immune thrombocytopenia, including disease‐specific treatments: a French nationwide cohort study
  18. Use of intravenous iron and risk of anaphylaxis: A multinational observational post‐authorisation safety study in Europe
  19. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study
  20. Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study
  21. Using epidemiological methods to quantify the risk of serious infections in children with atopic dermatitis
  22. Societal impact for patients with psoriasis: A nationwide Swedish register study
  23. Use of non‐insulin antidiabetic drugs in children and young adults – A Scandinavian drug utilization study from 2010–2019
  24. A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder
  25. Cancer risk in patients with primary immune thrombocytopenia – A Swedish nationwide register study
  26. Influence of statin‐potency on the risk of kidney disease – A nationwide cohort study using laboratory data
  27. <p>Assessing Safety of Direct Thrombin Inhibitors, Direct Factor Xa Inhibitors and Vitamin K Antagonists in Patients with Atrial Fibrillation: A Nation-Wide Propensity Score Matched Cohort from Sweden</p>
  28. Risk of common infections among individuals with psoriasis in Sweden: A nationwide cohort study comparing secukinumab to ustekinumab
  29. <p>The Occurrence of Metabolic Risk Factors Stratified by Psoriasis Severity: A Swedish Population-Based Matched Cohort Study</p>
  30. PD44-10 A STUDY OF CANCER OCCURRENCE IN USERS OF MIRABEGRON AND ANTIMUSCARINIC TREATMENTS FOR OVERACTIVE BLADDER
  31. Risk factors for severe bleeding events during warfarin treatment: the influence of sex, age, comorbidity and co-medication
  32. Methods for constructing treatment episodes and impact on exposure-outcome associations
  33. Patient characteristics when starting treatment and patterns of treatment in adults with chronic immune thrombocytopenia
  34. Impact of risk factors on the occurrence of arterial thrombosis and venous thromboembolism in adults with primary immune thrombocytopenia – Results from two nationwide cohorts
  35. Adult height is associated with risk of cancer and mortality in 5.5 million Swedish women and men
  36. Classification and characteristics of on‐label and off‐label apixaban use in Denmark and Sweden
  37. Exposure to antimuscarinic medications for treatment of overactive bladder and risk of lung cancer and colon cancer
  38. Risk Factors of Thrombosis in Adults with Primary Immune Thrombocytopenia. a French Nationwide Cohort Study
  39. Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom
  40. Effectiveness of risk minimization measures for the use of cilostazol in United Kingdom, Spain, Sweden, and Germany
  41. Young patients with risk factors prevalent in the elderly – differences in comorbidity depending on severity of psoriasis: a nationwide cross-sectional study in Swedish health registers
  42. Erratum
  43. Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study
  44. Methods for time-varying exposure related problems in pharmacoepidemiology: An overview
  45. Pharmacological agents preceding a diagnosis of immune thrombocytopenia in adult patients developing the chronic form: A Swedish national register study
  46. Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort study
  47. Palivizumab Exposure and the Risk of Atopic Dermatitis, Asthma and Allergic Rhinoconjunctivitis: A Cross-National, Population-Based Cohort Study
  48. Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany
  49. Palivizumab Exposure and the Risk of Autoimmune Disease: A Cross-National Cohort Study
  50. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries
  51. Increased susceptibility to infections before the diagnosis of immune thrombocytopenia
  52. Influence of baseline low-density lipoprotein cholesterol values on statin therapy persistence
  53. Incidence rates of atopic dermatitis, asthma, and allergic rhinoconjunctivitis in Danish and Swedish children
  54. Hormone therapy and risk of cardiovascular outcomes and mortality in women treated with statins
  55. It is possible to identify complex diseases using national health registers
  56. Use of palivizumab is underestimated in the Swedish Prescribed Drug Register – implications for register-based drug studies
  57. Birth Outcomes in Women with Inflammatory Bowel Disease
  58. Family history of cardiovascular disease and influence on statin therapy persistence
  59. Risks of Malignant and Non-Malignant Tumours in Tall Women Treated with High-Dose Oestrogen during Adolescence
  60. Complications From Inflammatory Bowel Disease During Pregnancy and Delivery
  61. Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden
  62. New modes of data partitioning based on PARS peak alignment for improved multivariate biomarker/biopattern detection in 1H-NMR spectroscopic metabolic profiling of urine
  63. Precision of prediction in second-order calibration, with focus on bilinear regression methods
  64. Second-order calibration: bilinear least squares regression and a simple alternative